View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBenevolentAI 향후 성장Future 기준 점검 2/6BenevolentAI (는) 각각 연간 72.4% 및 26.8% 수익과 수익이 증가할 것으로 예상됩니다.핵심 정보72.4%이익 성장률n/aEPS 성장률Pharmaceuticals 이익 성장23.7%매출 성장률26.8%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트14 Mar 2025최근 향후 성장 업데이트Breakeven Date Change • Sep 19Forecast to breakeven in 2026The 4 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2025. The company is expected to make a profit of UK£713.4k in 2026. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Breakeven Date Change • May 29Forecast to breakeven in 2026The 3 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 45% per year to 2025. The company is expected to make a profit of UK£1.25m in 2026. Average annual earnings growth of 63% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates공시 • Mar 14BenevolentAI Announces Delisting from Euronext Amsterdam Effective 13 March 2025BenevolentAI S.A. announced that their shares will be delisted from Euronext Amsterdam effective 13 March 2025.공시 • Feb 08BenevolentAI S.A. Proposes Delisting from Euronext Amsterdam N.VFollowing the announcement on 11 December 2024 and subsequent further detailed review and evaluation, the Board of BenevolentAI S.A. has concluded that delisting from Euronext Amsterdam N.V. (“Euronext”) and transitioning to a private company is in the best interests of the Company and its shareholders. The Board determined that the financial and administrative costs of maintaining a public listing are not justified by the benefits. By eliminating the significant costs associated with its public status, including legal, regulatory, financial, and administrative overheads, the Company can redeploy this capital towards core business activities that drive innovation and product development. This aims to deliver greater value to its shareholders, partners and ultimately benefit the patients it serves. The proposed Delisting and Merger of BenevolentAI into Osaka Holdings requires passing EGM Resolutions (as defined and set out below). It is important for shareholders to understand that should any of the Resolutions fail to pass, the Delisting and Merger will not proceed. Delisting will be implemented via a merger of BenevolentAI into Osaka Holdings. Osaka Holdings is currently a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg with its registered office at 9, rue de Bitbourg, L-1273 Luxembourg. It is not listed on any exchange and has no assets and no liabilities other than its share capital which will be reduced to zero on Merger. Upon the Merger, scheduled for completion on 12 March 2025, all the Company’s assets, liabilities, rights and obligations will transfers to Osaka Holdings under universal title of succession. If the Resolutions are passed at the EGM, the Merger will become effective once both BenevolentAI and Osaka Holdings have adopted the concurring approval decisions during their respective general meetings on the same day. Consequently, it is envisaged that the Delisting will become effective on 13 March 2025. Upon Delisting, the last day of trading in the class A shares and class A warrants will be 12 March 2025. The EGM will be held on 12 March 2025.공시 • Oct 17+ 1 more updateBenevolentAI S.A. Appoints Michael Brennan as Chief Financial OfficerBenevolentAI announced the appointment of Michael Brennan as Chief Financial Officer, further strengthening the Company’s leadership. A co-founder of BenevolentAI, Michael brings a wealth of expertise from senior roles across the biotechnology, technology and investment banking sectors. His appointment reflects the Company’s focus on strengthening its commercial and financial position and driving future growth.Reported Earnings • Sep 25First half 2024 earnings released: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)First half 2024 results: UK£0.20 loss per share (improved from UK£0.31 loss in 1H 2023). Net loss: UK£24.8m (loss narrowed 32% from 1H 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.New Risk • Sep 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£16m net loss in 2 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€86.6m market cap, or US$96.6m).Breakeven Date Change • Sep 19Forecast to breakeven in 2026The 4 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2025. The company is expected to make a profit of UK£713.4k in 2026. Average annual earnings growth of 58% is required to achieve expected profit on schedule.공시 • Sep 17BenevolentAI S.A. to Report First Half, 2024 Results on Sep 19, 2024BenevolentAI S.A. announced that they will report first half, 2024 results on Sep 19, 2024New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: UK£63m Forecast net loss in 3 years: UK£9.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (UK£9.9m net loss in 3 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€70.2m market cap, or US$78.3m).공시 • Jul 04BenevolentAI S.A. Announces CFO ChangesBenevolentAI S.A. announced a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms. Catherine Isted stepping down from her role as Chief Financial Officer. Mr. Tom Holgate, who has been at BenevolentAI for nearly seven years, will continue in his role as Group Finance Director, ensuring continuity and leveraging his extensive understanding of the Company's financial landscape to lead several pivotal financial initiatives. The company is intensifying its efforts to capitalise on the expanding opportunities within the rapidly maturing 'techbio' sector. BenevolentAI's strong momentum is underscored by last week’s successful integration of a novel target in Systemic Lupus Erythematosus into AstraZeneca's portfolio, marking yet another significant milestone for the Company and the second major collaboration milestone achieved with AstraZeneca this year. The Board's review further highlighted the need to adopt a more dynamic and entrepreneurial approach across the Company’s leadership, business development activities, and internal management structures. These changes are designed to expand the Company's market share in the AI-driven drug discovery sector, accelerate the development of its internal pipelines, and forge new strategic collaborations.Breakeven Date Change • May 29Forecast to breakeven in 2026The 3 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 45% per year to 2025. The company is expected to make a profit of UK£1.25m in 2026. Average annual earnings growth of 63% is required to achieve expected profit on schedule.공시 • May 03Benevolentai S.A. Announces Directorate ChangesBenevolentAI announced that all resolutions proposed at its Annual General Meeting were duly passed. In line with the AGM resolutions, Mr. Peter Allen, Mr. Kenneth Mulvany, Mr. Ian Nicholson and Mr. Jeremy Sohn, have joined the Board of the Company as Non-Executive Directors. As per the Company’s announcement of 15 April 2024, the close of the AGM has also resulted in the resignations of Dr François Nader, Dr Olivier Brandicourt, Dr Susan Liautaud and Mr. Marcello Damiani, as Non-Executive Directors of BenevolentAI, becoming effective. The Board now consists of eight persons, seven Non-Executive Directors and Dr Joerg Moeller, CEO and Executive Director of the Company. The position of the Chair of the Board and the composition of Board Committees will be determined at the time of the first board meeting and will be communicated thereafter.공시 • Apr 15BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024BenevolentAI S.A. announced that Dr. François Nader, Chair of the Board, Dr. Olivier Brandicourt, Dr. Susan Liautaud and Mr. Marcello Damiani, all Non-Executive Directors, will resign as directors of BenevolentAI effective as of the close of the Company’s AGM on 2 May 2024.공시 • Apr 03Kenneth Mulvany Sends a Letter to Benovelent AIOn April 2, 2024, Kenneth Mulvany stated that he has sent a letter to Benovelent AI, stating that he has raised concerns about the Company's cost management, business development resourcing, strategy, investor relations and governance. In addition, Kenneth Mulvany stated that in his letter he declared his intention to nominate a slate of director candidates that aim to strengthen governance and accountability, invigorate the Company's business development, sharpen its strategic focus, offer clear market communication, and rebuild confidence among our investors and stakeholders, and this declaration paves the way for him to seek the support of shareholders at the forthcoming Annual General Meeting, for Board reform. Further, Kenneth Mulvany stated that he will be focusing the Board's efforts to prioritize stringent cost management and revenue growth, along with expanding strategic partnerships and with the support of shareholders, he prepared to take on a director role.공시 • Mar 20+ 1 more updateBenevolentAI S.A., Annual General Meeting, May 02, 2024BenevolentAI S.A., Annual General Meeting, May 02, 2024, at 14:00 Central European Standard Time. Location: 2, place Winston Churchill, L-1340 LuxembourgNew Risk • Mar 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£12m net loss in 2 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€89.6m market cap, or US$97.4m).Reported Earnings • Mar 18Full year 2023 earnings released: UK£0.54 loss per share (vs UK£1.50 loss in FY 2022)Full year 2023 results: UK£0.54 loss per share (improved from UK£1.50 loss in FY 2022). Net loss: UK£63.3m (loss narrowed 61% from FY 2022). Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.Board Change • Mar 07High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Francois Nader is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.이익 및 매출 성장 예측DB:2XA - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2027N/AN/AN/AN/A112/31/202665303335112/31/202515-41-39-35212/31/20248-55-49-5026/30/20245-51-48-47N/A3/31/20246-57-53-52N/A12/31/20237-63-58-57N/A9/30/20239-61-70-69N/A6/30/202311-59-82-80N/A3/31/202311-112-80-79N/A12/31/202211-164-78-77N/A9/30/20229-186-76-74N/A6/30/20228-208-73-72N/A3/31/20226-158-61-60N/A12/31/20215-108-50-49N/A12/31/20207-55-36-35N/A12/31/20195-48-30-29N/A12/31/20187-27-42-38N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 2XA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 2XA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 2XA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 2XA 의 수익(연간 26.8%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 2XA 의 수익(연간 26.8%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 2XA의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/03/17 14:49종가2025/03/12 00:00수익2024/06/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BenevolentAI S.A.는 4명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rajan SharmaGoldman SachsRichard VosserJ.P. MorganJames GordonJ.P. Morgan1명의 분석가 더 보기
Breakeven Date Change • Sep 19Forecast to breakeven in 2026The 4 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2025. The company is expected to make a profit of UK£713.4k in 2026. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Breakeven Date Change • May 29Forecast to breakeven in 2026The 3 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 45% per year to 2025. The company is expected to make a profit of UK£1.25m in 2026. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
공시 • Mar 14BenevolentAI Announces Delisting from Euronext Amsterdam Effective 13 March 2025BenevolentAI S.A. announced that their shares will be delisted from Euronext Amsterdam effective 13 March 2025.
공시 • Feb 08BenevolentAI S.A. Proposes Delisting from Euronext Amsterdam N.VFollowing the announcement on 11 December 2024 and subsequent further detailed review and evaluation, the Board of BenevolentAI S.A. has concluded that delisting from Euronext Amsterdam N.V. (“Euronext”) and transitioning to a private company is in the best interests of the Company and its shareholders. The Board determined that the financial and administrative costs of maintaining a public listing are not justified by the benefits. By eliminating the significant costs associated with its public status, including legal, regulatory, financial, and administrative overheads, the Company can redeploy this capital towards core business activities that drive innovation and product development. This aims to deliver greater value to its shareholders, partners and ultimately benefit the patients it serves. The proposed Delisting and Merger of BenevolentAI into Osaka Holdings requires passing EGM Resolutions (as defined and set out below). It is important for shareholders to understand that should any of the Resolutions fail to pass, the Delisting and Merger will not proceed. Delisting will be implemented via a merger of BenevolentAI into Osaka Holdings. Osaka Holdings is currently a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg with its registered office at 9, rue de Bitbourg, L-1273 Luxembourg. It is not listed on any exchange and has no assets and no liabilities other than its share capital which will be reduced to zero on Merger. Upon the Merger, scheduled for completion on 12 March 2025, all the Company’s assets, liabilities, rights and obligations will transfers to Osaka Holdings under universal title of succession. If the Resolutions are passed at the EGM, the Merger will become effective once both BenevolentAI and Osaka Holdings have adopted the concurring approval decisions during their respective general meetings on the same day. Consequently, it is envisaged that the Delisting will become effective on 13 March 2025. Upon Delisting, the last day of trading in the class A shares and class A warrants will be 12 March 2025. The EGM will be held on 12 March 2025.
공시 • Oct 17+ 1 more updateBenevolentAI S.A. Appoints Michael Brennan as Chief Financial OfficerBenevolentAI announced the appointment of Michael Brennan as Chief Financial Officer, further strengthening the Company’s leadership. A co-founder of BenevolentAI, Michael brings a wealth of expertise from senior roles across the biotechnology, technology and investment banking sectors. His appointment reflects the Company’s focus on strengthening its commercial and financial position and driving future growth.
Reported Earnings • Sep 25First half 2024 earnings released: UK£0.20 loss per share (vs UK£0.31 loss in 1H 2023)First half 2024 results: UK£0.20 loss per share (improved from UK£0.31 loss in 1H 2023). Net loss: UK£24.8m (loss narrowed 32% from 1H 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany.
New Risk • Sep 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£16m net loss in 2 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€86.6m market cap, or US$96.6m).
Breakeven Date Change • Sep 19Forecast to breakeven in 2026The 4 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2025. The company is expected to make a profit of UK£713.4k in 2026. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
공시 • Sep 17BenevolentAI S.A. to Report First Half, 2024 Results on Sep 19, 2024BenevolentAI S.A. announced that they will report first half, 2024 results on Sep 19, 2024
New Risk • Aug 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: UK£63m Forecast net loss in 3 years: UK£9.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (UK£9.9m net loss in 3 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€70.2m market cap, or US$78.3m).
공시 • Jul 04BenevolentAI S.A. Announces CFO ChangesBenevolentAI S.A. announced a change to its Executive Leadership Team (ELT) following the recent Annual General Meeting and the election of a new Board of Directors. In a move to better enhance operational efficiency and strategic focus, the Board initiated a leadership review to better support BenevolentAI's ambitious growth plans. The results of the review include Ms. Catherine Isted stepping down from her role as Chief Financial Officer. Mr. Tom Holgate, who has been at BenevolentAI for nearly seven years, will continue in his role as Group Finance Director, ensuring continuity and leveraging his extensive understanding of the Company's financial landscape to lead several pivotal financial initiatives. The company is intensifying its efforts to capitalise on the expanding opportunities within the rapidly maturing 'techbio' sector. BenevolentAI's strong momentum is underscored by last week’s successful integration of a novel target in Systemic Lupus Erythematosus into AstraZeneca's portfolio, marking yet another significant milestone for the Company and the second major collaboration milestone achieved with AstraZeneca this year. The Board's review further highlighted the need to adopt a more dynamic and entrepreneurial approach across the Company’s leadership, business development activities, and internal management structures. These changes are designed to expand the Company's market share in the AI-driven drug discovery sector, accelerate the development of its internal pipelines, and forge new strategic collaborations.
Breakeven Date Change • May 29Forecast to breakeven in 2026The 3 analysts covering BenevolentAI expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 45% per year to 2025. The company is expected to make a profit of UK£1.25m in 2026. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
공시 • May 03Benevolentai S.A. Announces Directorate ChangesBenevolentAI announced that all resolutions proposed at its Annual General Meeting were duly passed. In line with the AGM resolutions, Mr. Peter Allen, Mr. Kenneth Mulvany, Mr. Ian Nicholson and Mr. Jeremy Sohn, have joined the Board of the Company as Non-Executive Directors. As per the Company’s announcement of 15 April 2024, the close of the AGM has also resulted in the resignations of Dr François Nader, Dr Olivier Brandicourt, Dr Susan Liautaud and Mr. Marcello Damiani, as Non-Executive Directors of BenevolentAI, becoming effective. The Board now consists of eight persons, seven Non-Executive Directors and Dr Joerg Moeller, CEO and Executive Director of the Company. The position of the Chair of the Board and the composition of Board Committees will be determined at the time of the first board meeting and will be communicated thereafter.
공시 • Apr 15BenevolentAI S.A. Announces Board Resignations, Effective from May 2, 2024BenevolentAI S.A. announced that Dr. François Nader, Chair of the Board, Dr. Olivier Brandicourt, Dr. Susan Liautaud and Mr. Marcello Damiani, all Non-Executive Directors, will resign as directors of BenevolentAI effective as of the close of the Company’s AGM on 2 May 2024.
공시 • Apr 03Kenneth Mulvany Sends a Letter to Benovelent AIOn April 2, 2024, Kenneth Mulvany stated that he has sent a letter to Benovelent AI, stating that he has raised concerns about the Company's cost management, business development resourcing, strategy, investor relations and governance. In addition, Kenneth Mulvany stated that in his letter he declared his intention to nominate a slate of director candidates that aim to strengthen governance and accountability, invigorate the Company's business development, sharpen its strategic focus, offer clear market communication, and rebuild confidence among our investors and stakeholders, and this declaration paves the way for him to seek the support of shareholders at the forthcoming Annual General Meeting, for Board reform. Further, Kenneth Mulvany stated that he will be focusing the Board's efforts to prioritize stringent cost management and revenue growth, along with expanding strategic partnerships and with the support of shareholders, he prepared to take on a director role.
공시 • Mar 20+ 1 more updateBenevolentAI S.A., Annual General Meeting, May 02, 2024BenevolentAI S.A., Annual General Meeting, May 02, 2024, at 14:00 Central European Standard Time. Location: 2, place Winston Churchill, L-1340 Luxembourg
New Risk • Mar 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (UK£12m net loss in 2 years). Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (€89.6m market cap, or US$97.4m).
Reported Earnings • Mar 18Full year 2023 earnings released: UK£0.54 loss per share (vs UK£1.50 loss in FY 2022)Full year 2023 results: UK£0.54 loss per share (improved from UK£1.50 loss in FY 2022). Net loss: UK£63.3m (loss narrowed 61% from FY 2022). Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany.
Board Change • Mar 07High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Chairman Francois Nader is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.